A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Recruiting now Phase 2 NCT07094516
Run by Novartis Pharmaceuticals · for 50 to 85 · All sexes
What this study is about
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Who can join (things the study team will check)
✅ You may be able to join if…
- Male or female participants 50 to 85 years of age
- Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD
- Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0
- Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging
- Reliable study partner who can accompany the participant at study visits
- If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment
🚫 You may not be able to join if…
- Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia.
- History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study
- Transient ischemic attacks (TIA) or stroke occurring within 12 months
- Clinical evidence of liver or renal disease/injury
- Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis
- Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures
- Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening
- Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes
- Taking any prohibited medications Other protocol-defined inclusion/exclusion criteria may apply
Where this trial is running
- Banner Alzheimers Institute, Phoenix, Arizona, United States
- Irvine Center for Clinical Research, Irvine, California, United States
- University of California San Diego, La Jolla, California, United States
- University of California at Los Angeles, Los Angeles, California, United States
- Jem Research Institute, Atlantis, Florida, United States
- Visionary Investigators Network, Aventura, Florida, United States
- K2 Medical Research LLC, Maitland, Florida, United States
- K2 Medical Research LLC, Maitland, Florida, United States
- Renstar Medical Research, Ocala, Florida, United States
- Charter Research The Villages, The Villages, Florida, United States
- Alzheimers Research Treatment Ctr, Wellington, Florida, United States
- Alzheimers Research Treatment Ctr, Wellington, Florida, United States
+ 62 more sites.
Who to contact
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07094516.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.